The vials are being retrieved from the U.K., Germany, Romania, the Netherlands, Ireland, Sweden, Finland and Spain, according to BMS spokesman Ken Dominski. The recall was issued because of concerns the vials in the affected batches had not been fully filled.
Smiths Medical, the healthcare arm of British giant Smiths Group, watched pricing pressures and the medical device tax erode its sales in fiscal 2013, but the company's CEO said he still wants to keep the medical device business.
Abbott Laboratories won a CE mark for its FreeStyle Optium Neo Blood Glucose and Ketone Monitoring System, expanding its presence on the European diabetes market with a next-gen device.
Medical device regulatory reform in Europe faced another setback this week. A European Parliament committee has once again tabled a vote on tougher new regulations, putting it off for the second time since July.
Medtronic is opening up a $10.2 million R&D operation in Galway, Ireland, planning to put local minds to work on developing new cardiovascular devices.
Japanese drugmaker Eisai said a site in the U.K. has won approval from the FDA to manufacture its new epilepsy drug, which the FDA approved nearly a year ago. Now it just needs the Drug Enforcement Agency to quit sitting on it so it can get to market with Fycompa, a potential blockbuster.
AstraZeneca is looking to add an aseptic drug manufacturing facility at its Macclesfield, U.K., site, the same complex where manufacturing has drawn attention from U.S. authorities for reasons no one will discuss.
The European Public Health Alliance (EPHA), a network of nonprofits and NGOs, updated its position on medical devices one year after it released its original paper. Overall, the group wants tighter regulations for the med tech industry.
You can now count the Australian government as a major supporter of regenerative medicine research. Prime Minister Kevin Rudd has unveiled a $250 million public/private fund to back new work in the field, taking a stake in early-stage labor that will take years--and years--to pay off.
Few people in the U.K.'s biotech industry have as much influence as Chris Evans. That influence was on full display this week after the high-flying investor took a personal, million-dollar stake in the regenerative medicine company ReNeuron, which is being refinanced and moved to Wales as part of a Welsh government effort to build a biotech hub in the region.